Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients
暂无分享,去创建一个
S. Genovesi | D. Toni | M. Bo | P. Verdecchia | G. Di Minno | G. di Pasquale | M. Molteni
[1] Ulrich Schotten,et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.
[2] A. Santoro,et al. Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study , 2017, Journal of Nephrology.
[3] E. Manzato,et al. Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non‐valvular atrial fibrillation , 2016, Journal of thrombosis and haemostasis : JTH.
[4] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[5] D. Brancaccio,et al. Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study , 2016, American Journal of Nephrology.
[6] A. Tripodi,et al. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures , 2016, Journal of thrombosis and haemostasis : JTH.
[7] P. Verhamme,et al. Reversal of dabigatran by idarucizumab: when and how? , 2016, Expert review of hematology.
[8] G. Lip,et al. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. , 2016, JAMA cardiology.
[9] T. Steiner,et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation , 2016, Critical Care.
[10] P. Schulman,et al. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.
[11] M. Tinetti,et al. Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. , 2016, JAMA cardiology.
[12] F. Gaita,et al. Effects of Oral Anticoagulant Therapy in Medical Inpatients ≥65 Years With Atrial Fibrillation. , 2016, The American journal of cardiology.
[13] G. Caleb Alexander,et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation , 2016, Journal of the American Heart Association.
[14] R. Rossaint,et al. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model , 2015, Thrombosis and Haemostasis.
[15] A. Camm,et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[16] A. Själander,et al. Warfarin persistence among stroke patients with atrial fibrillation. , 2015, Thrombosis research.
[17] C. Spivey,et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation , 2015, Current medical research and opinion.
[18] A. Di Minno,et al. Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. , 2015, Blood reviews.
[19] T. Steiner,et al. Idarucizumab for Dabigatran Reversal. , 2015, The New England journal of medicine.
[20] Bcps,et al. Idarucizumab for dabigatran reversal , 2015 .
[21] S. Yusuf,et al. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. , 2015, Journal of the American College of Cardiology.
[22] F. Gaita,et al. Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study. , 2015, International journal of cardiology.
[23] S. Corrao,et al. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. , 2015, European journal of internal medicine.
[24] M. Turakhia,et al. Site-level variation in and practices associated with dabigatran adherence. , 2015, JAMA.
[25] H. Heidbuchel,et al. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[26] A. Santoro,et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] E. Edelman,et al. Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.
[28] Mark Levenson,et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.
[29] M. Lamberts,et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.
[30] J. Halperin,et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. , 2014, The Canadian journal of cardiology.
[31] G. Lip,et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. , 2014, The American journal of medicine.
[32] S. Goldhaber,et al. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis , 2014, Circulation.
[33] R. Rossaint,et al. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model , 2014, Critical Care.
[34] A. Abdul-Rahim,et al. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation , 2014, Heart.
[35] A. Santoro,et al. The nephrologist’s anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation , 2014, Journal of Nephrology.
[36] G. Lip,et al. Patient outcomes using the European label for dabigatran , 2013, Thrombosis and Haemostasis.
[37] S. Yusuf,et al. Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis , 2013, Circulation.
[38] Emily C. O'Brien,et al. Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). , 2014, American heart journal.
[39] A. Maggioni,et al. Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study. , 2013, International journal of cardiology.
[40] J. Eikelboom,et al. Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. , 2013, Circulation.
[41] L. Ferrucci,et al. Glomerular Filtration Rate Equations Overestimate Creatinine Clearance in Older Individuals Enrolled in the Baltimore Longitudinal Study on Aging: Impact on Renal Drug Dosing , 2013, Pharmacotherapy.
[42] R. Mathur,et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study , 2013, BMJ Open.
[43] S. Shafi,et al. A case of dabigatran-associated acute renal failure. , 2013, WMJ : official publication of the State Medical Society of Wisconsin.
[44] J. Eikelboom,et al. New oral anticoagulants in elderly patients. , 2013, Best practice & research. Clinical haematology.
[45] D. Chae,et al. The Occurrence of Warfarin-Related Nephropathy and Effects on Renal and Patient Outcomes in Korean Patients , 2013, PloS one.
[46] T. Gomes,et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation , 2013, Canadian Medical Association Journal.
[47] E. Schaeffner,et al. Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older , 2012, Annals of Internal Medicine.
[48] E. Teal,et al. Perceived or Actual Barriers to Warfarin Use in Atrial Fibrillation Based on Electronic Medical Records , 2012, American journal of therapeutics.
[49] L. Køber,et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.
[50] J. Cracowski,et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.
[51] Mark Crowther,et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[52] W. Ageno,et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis , 2012 .
[53] W. Ageno,et al. Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Oral Anticoagulant Therapy : Antithrombotic , 2012 .
[54] C. Richards,et al. Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.
[55] G. Mead,et al. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. , 2011, Age and ageing.
[56] P. Kamphuisen,et al. Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.
[57] B. Rovin,et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. , 2011, Journal of the American Society of Nephrology : JASN.
[58] W. Ageno,et al. Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation , 2011, Circulation.
[59] B. Rovin,et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. , 2011, Kidney international.
[60] Bertram L Kasiske,et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.
[61] S. Yusuf,et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.
[62] G. Lip,et al. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. , 2011, Journal of the American College of Cardiology.
[63] Elsayed Z Soliman,et al. Association of Chronic Kidney Disease With Atrial Fibrillation Among Adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2011, Circulation. Arrhythmia and electrophysiology.
[64] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[65] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[66] L. Hebert,et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[67] D. Singer,et al. The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation , 2009, Annals of Internal Medicine.
[68] M. Crowther,et al. Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose , 2009, Transfusion.
[69] W. Baker,et al. Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States , 2009, Journal of managed care pharmacy : JMCP.
[70] D. Singer,et al. Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.
[71] D. Singer,et al. Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.
[72] S. Frostick,et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.
[73] S. Frostick,et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.
[74] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[75] Susan Regan,et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.
[76] Tom Greene,et al. Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.
[77] E. Hylek,et al. Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation , 2006, Stroke.
[78] M. Rich,et al. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. , 2005, The American journal of medicine.
[79] F. Molnar,et al. The risk of hemorrhagic complications in hospital in-patients who fall while receiving antithrombotic therapy , 2005, Thrombosis journal.
[80] A. Garg,et al. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). , 2002, Journal of the American Society of Nephrology : JASN.
[81] D. Singer,et al. Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.
[82] A. Laupacis,et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. , 1999, Archives of internal medicine.
[83] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.